Literature DB >> 14404857

The hematologic toxicity of pyrimethamine (daraprim) in man.

H E KAUFMAN, P H GEISLER.   

Abstract

Entities:  

Keywords:  ANTIMALARIALS/toxicology; TOXOPLASMOSIS/therapy; UVEITIS/therapy

Mesh：

Substances：

Year:  1960        PMID： 14404857     DOI： 10.1001/archopht.1960.01840010142016

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  9 in total

1.  Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

Authors:  N Schöler; K Krause; O Kayser; R H Müller; K Borner; H Hahn; O Liesenfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine.

Authors:  Dorte Remmer Schmidt; Birthe Hogh; Ole Andersen; Steen Honoré Hansen; Kim Dalhoff; Eskild Petersen
Journal:  Eur J Pediatr       Date:  2005-08-20       Impact factor: 3.183

3.  Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling.

Authors:  Sam Salman; Francisca Baiwog; Madhu Page-Sharp; Susan Griffin; Harin A Karunajeewa; Ivo Mueller; Stephen J Rogerson; Peter M Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Ocular toxoplasmosis in AIDS patients.

Authors:  D J Gagliuso; S A Teich; A H Friedman; J Orellana
Journal:  Trans Am Ophthalmol Soc       Date:  1990

5.  Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

Authors:  J Chan; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

6.  Effect of roxithromycin on acute toxoplasmosis in mice.

Authors:  H R Chang; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation.

Authors:  Mark J Landau; Hitesh Sharma; Karen S Anderson
Journal:  Protein Sci       Date:  2013-08-01       Impact factor: 6.725

Review 8.  Current recommendations and future prospects in the treatment of toxoplasmosis.

Authors:  R E McCabe; S Oster
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

9.  A novel PAN/apple domain-containing protein from Toxoplasma gondii: characterization and receptor identification.

Authors:  Haiyan Gong; Kyousuke Kobayashi; Tatsuki Sugi; Hitoshi Takemae; Hitomi Kurokawa; Taisuke Horimoto; Hiroomi Akashi; Kentaro Kato
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.